{"id":"NCT02485717","sponsor":"ParaPRO LLC","briefTitle":"Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies","officialTitle":"A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy and Pharmacokinetics of Natroba™ (Spinosad) for the Treatment of Scabies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-02","primaryCompletion":"2018-06-25","completion":"2018-06-25","firstPosted":"2015-06-30","resultsPosted":"2019-01-16","lastUpdate":"2021-05-19"},"enrollment":291,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Scabies"],"interventions":[{"type":"DRUG","name":"spinosad topical suspension, 0.9%","otherNames":["Natroba (spinosad) Topical Suspension, 0.9%"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Natroba (spinosad)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To assess the safety and efficacy of Natroba (spinosad) topical suspension versus placebo for the clinical cure of scabies after a single treatment. The trial will also assess the pharmacokinetics (PK) of spinosad and benzyl alcohol following a single dose of Natroba™ in pediatric subjects 4-16 years of age. These subjects will be a separate population of pediatric subjects.","primaryOutcome":{"measure":"Number of Index Subjects Completely Cured of Scabies After a Single Treatment","timeFrame":"28 days after treatment","effectByArm":[{"arm":"Natroba (Spinosad)","deltaMin":30,"sd":null},{"arm":"Placebo","deltaMin":20,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":142},"commonTop":[]}}